Clinical Trials - October 29, 2014
New study planned for Diamyd’s diabetes vaccine
In order to increase the scientific value of the research on preventative treatment with the Diamyd® diabetes vaccine, the research team at Lund University, who have been driving the DiAPREV-IT study since 2009, decided to expand the dataset with additional children at high risk of presenting with type 1 diabetes. Therefore, after discussions with the […]
Uncategorized - November 15, 2013
World Diabetes Day November 14th
Diabetes people with low levels of physical activity are at greater risk of cardiovascular disease shows new study. The risk of cardiovascular complications in people with type 2 diabetes is directly related to the frequency and duration of physical exercise, according to results of a large follow-up study reported yesterday on World Diabetes Day. Notably, […]
Uncategorized - November 7, 2013
Novo Nordisk supports diabetes researchers
Novo Nordisk and Oxford University team up to further enhance diabetes research and help the new generation of research leaders. The two have established an international fellowship program with the aim to support the development and career of young, exceptional research talent within diabetes. The new partnership will establish postdoctoral fellowship opportunities that will be […]
Science Award - September 24, 2013
Major prize for Lund diabetes researcher
This year’s Fernström Foundation Nordic Prize, with prize money of SEK 1 million, goes to the internationally renowned diabetes researcher Leif Groop from Lund University in Sweden. Leif Groop’s speciality has been referred to as ‘gene fishing’. It involves fishing up the genes that contribute to diabetes in one of its forms from the human […]
Collaboration - September 3, 2013
Zealand in R&D agreement with Lilly
The Danish pharma company Zealand Pharma announces peptide drug research and development collaboration agreement with Eli Lilly and Company. The two companies will together design and develop potentially novel therapeutic peptides for Type 2 diabetes and obesity. The development will be based on a novel approach discovered by Lilly and the two companies will share […]
Drug Development Pharma - August 6, 2013
Green light for diabetes treatment
The European Medicines Agency, EMA, has concluded that GLP-1 based treatments do not pose new safety concerns for patients with type 2 diabetes. Earlier this year, a study was published that indicated that drugs based on GLP-1 increase the risk of developing pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia. GLP-1, glucagon-like-peptide-1, is a […]
